Comment on: Have we reached the limits for the treatment of diabetic nephropathy?

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.23, Iss.6, 2014-06, pp. : 883-884

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Role of Sulodexide in the Treatment of Diabetic Nephropathy

By Weiss Ram

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2681-2696

Adis International

Access to resources Recommend Favorite

Agents in development for the treatment of diabetic nephropathy

By Fukami Kei Cooper Mark E Forbes Josephine M

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 3, 2005-03 ,pp. : 279-294

Informa Healthcare

Access to resources Recommend Favorite

A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy

By Thomas Merlin

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 8, 2012-08 ,pp. : 1015-1022

Informa Healthcare

Access to resources Recommend Favorite

Prevention and Treatment of Diabetic Nephropathy in Older Patients

By Jungmann E.

Drugs & Aging, Vol. 20, Iss. 6, 2003-01 ,pp. : 419-435

Adis International

Access to resources Recommend Favorite

New trends in the treatment of diabetic nephropathy in children

By Corcia Giovanna di Trotta Daniela Verrotti Alberto Chiarelli Francesco

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 8, 2002-08 ,pp. : 1169-1176

Informa Healthcare

Access to resources Recommend Favorite